+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Guardant Health Inc (GH) - Product Pipeline Analysis, 2021 Update

  • ID: 5367369
  • Company Profile
  • June 2021
  • 48 pages
  • GlobalData

FEATURED COMPANIES

  • BioGenex Laboratories Inc
  • ElSohly Laboratories Inc
  • Illumina Inc
  • InVitae Corp
  • NantHealth Inc
  • Natera Inc
  • MORE
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Guardant Health Inc (Guardant Health) is a precision oncology company that commercializes novel therapeutics for cancer. The company develops proprietary digital sequencing technology used to detect individual genomic alterations. It offers Guardant360, a tool for early cancer detection used during cancer treatment for residual disease monitoring and recurrence monitoring. Guardant Health also develops a cloud-based information platform for liquid biopsy-based genomic testing in cancer treatments. The company provides somatic alterations across all solid tumor sites. Guardant Health is headquartered in Redwood City, California, the US.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and helps to create effective counter strategies to gain a competitive advantage.

Scope
  • The report reviews the detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company Guardant Health Inc
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides a detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design, trial status and phase, estimated start and end date
Reasons to Buy
  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain a competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • BioGenex Laboratories Inc
  • ElSohly Laboratories Inc
  • Illumina Inc
  • InVitae Corp
  • NantHealth Inc
  • Natera Inc
  • MORE
Guardant Health Inc Company Overview
  • Guardant Health Inc Company Snapshot
  • Guardant Health Inc Pipeline Products and Ongoing Clinical Trials Overview
  • Guardant Health Inc - Pipeline Analysis Overview
  • Guardant Health Inc - Key Facts
  • Guardant Health Inc - Major Products and Services
  • Guardant Health Inc Pipeline Products by Development Stage
  • Guardant Health Inc Ongoing Clinical Trials by Trial Status
Guardant Health Inc Pipeline Products Overview
  • Anti-RSP03 Antibody Based Blood Test
  • Anti-RSP03 Antibody Based Blood Test Product Overview
  • cfDNA Diagnostic Assay
  • cfDNA Diagnostic Assay Product Overview
  • Gene-Based Test - Lung Cancer
  • Gene-Based Test - Lung Cancer Product Overview
  • Gene-Based Test - Lung Cancer Clinical Trial
  • Guardant360 CDx
  • Guardant360 CDx Product Overview
  • Guardant360 CDx Clinical Trial
  • Guardant360 CDx - Enhertu
  • Guardant360 CDx - Enhertu Product Overview
  • Guardant360 CDx Test - Amivantamab
  • Guardant360 CDx Test - Amivantamab Product Overview
  • Guardant360 CDx Test - Elacestrant
  • Guardant360 CDx Test - Elacestrant Product Overview
  • Guardant360 CDx Test - Elacestrant Clinical Trial
  • Guardant360 CDx Test - Lumakras
  • Guardant360 CDx Test - Lumakras Product Overview
  • Guardant360 CDx Test - Lumakras Clinical Trial
  • Guardant360 CDx Test - Pembrolizumab
  • Guardant360 CDx Test - Pembrolizumab Product Overview
  • Guardant360 CDx Test - Tepotinib
  • Guardant360 CDx Test - Tepotinib Product Overview
  • Guardant360 Companion Diagnostic Assay - Glesatinib
  • Guardant360 Companion Diagnostic Assay - Glesatinib Product Overview
  • GuardantOMNI Test - Imfinzi
  • GuardantOMNI Test - Imfinzi Product Overview
  • LUNAR-2 Assay
  • LUNAR-2 Assay Product Overview
  • LUNAR-2 Assay Clinical Trial
  • Next-Generation CGP Tissue Assay
  • Next-Generation CGP Tissue Assay Product Overview
Guardant Health Inc - Key Competitors

Guardant Health Inc - Key Employees

Guardant Health Inc - Locations and Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Recent Developments
  • Guardant Health Inc, Recent Developments
  • May 03, 2021: Guardant Health Appoints Craig Eagle, MD as Chief Medical Officer
  • Apr 29, 2021: Guardant Health to Participate in the BofA Securities 2021 Healthcare Conference
  • Feb 17, 2021: Guardant Health to Participate in Upcoming Investor Conferences
  • Jan 18, 2021: Guardant Health and Vall d’Hebron Institute of Oncology announce partnership to establish first guardant-based liquid biopsy testing service in Europe
  • Sep 04, 2020: Diagnostic Methods Benefit from Rapidly Advancing Technologies
  • Jul 21, 2020: Guardant Health Announces Webcast of Second Quarter Financial Results on August 6, 2020
  • Feb 24, 2020: Guardant Health reports fourth quarter and full year 2019 financial results and provides full year 2020 outlook
  • Feb 10, 2020: Guardant Health to Report Fourth Quarter and Full Year 2019 Financial Results on February 24, 2020
  • Jan 21, 2020: Guardant Health appoints High-Tech-Veteran Kumud Kalia Chief Information Officer
  • Jan 13, 2020: Guardant Health, NRG Oncology begin NRG-GI005 COBRA trial
Appendix
  • Methodology
  • About the Publisher
List of Tables
  • Guardant Health Inc Pipeline Products and Ongoing Clinical Trials Overview
  • Guardant Health Inc Pipeline Products by Equipment Type
  • Guardant Health Inc Pipeline Products by Indication
  • Guardant Health Inc Ongoing Clinical Trials by Trial Status
  • Guardant Health Inc, Key Facts
  • Guardant Health Inc, Major Products and Services
  • Guardant Health Inc Number of Pipeline Products by Development Stage
  • Guardant Health Inc Pipeline Products Summary by Development Stage
  • Guardant Health Inc Ongoing Clinical Trials by Trial Status
  • Guardant Health Inc Ongoing Clinical Trials Summary
  • Anti-RSP03 Antibody Based Blood Test - Product Status
  • Anti-RSP03 Antibody Based Blood Test - Product Description
  • cfDNA Diagnostic Assay - Product Status
  • cfDNA Diagnostic Assay - Product Description
  • Gene-Based Test - Lung Cancer - Product Status
  • Gene-Based Test - Lung Cancer - Product Description
  • Gene-Based Test - Lung Cancer - Prospective Feasibility Study of Cell Free Circulating Tumor DNA for the Diagnosis and Treatment Monitoring in Early-stage Non-small Cell Lung Cancer
  • Guardant360 CDx - Product Status
  • Guardant360 CDx - Product Description
  • Guardant360 CDx - A Multiple Parallel Cohort, Multi-centre Phase IIa Trial Aiming to Provide Proof of Principle Efficacy for Designated Targeted Therapies in Patients with Advanced Breast Cancer Where the Targetable Mutation is Identified Through ctDNA
  • Guardant360 CDx - A Prospective Observational Study on the Efficacy of Multiplex Genetic Analysis by Means of a Next-generation Sequencer Using Cell-free DNA
  • Guardant360 CDx - An Ambitious Multi-arm, Multi-site Umbrella Trial to Study Blood Test for Early Cancer Detection
  • Guardant360 CDx - Guardant360 Related Clinical Outcomes in Patients Who Share Medical Records-breast Cancer
  • Guardant360 CDx - Multicenter Phase II Study to Evaluate Efficacy and Safety of Combination Therapy with Trastuzumab and Pertuzumab in Patients with HER2-positive Metastatic Colorectal Cancer
  • Guardant360 CDx - Next Generation Personalized tX(Therapy) with Plasma DNA Trial-2 in Refractory Solid Tumors (The NEXT-2 Trial)
  • Guardant360 CDx - Open-label, Phase II Study of Trastuzumab in Combination with Lapatinib (Cohort A) or Pertuzumab in Combination with Trastuzumab-emtansine (Cohort B) in Patients with HER2-positive Metastatic Colorectal Cancer: The HERACLES (HER2 Amplification for Colo-rectal Cancer Enhanced Stratification)Trial
  • Guardant360 CDx - Research on Liquid Biopsy in Patients with Gastrointestinal and Abdominal Malignancies, Including Colorectal Cancer
  • Guardant360 CDx - Enhertu - Product Status
  • Guardant360 CDx - Enhertu - Product Description
  • Guardant360 CDx Test - Amivantamab - Product Status
  • Guardant360 CDx Test - Amivantamab - Product Description
  • Guardant360 CDx Test - Elacestrant - Product Status
  • Guardant360 CDx Test - Elacestrant - Product Description
  • Guardant360 CDx Test - Elacestrant - Elacestrant Monotherapy Vs. Standard of Care for the Treatment of Patients with ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase III Randomized, Open-label, Active-controlled, Multicenter Trial
  • Guardant360 CDx Test - Lumakras - Product Status
  • Guardant360 CDx Test - Lumakras - Product Description
  • Guardant360 CDx Test - Lumakras - A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects with Advanced Solid Tumors with KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects with Advanced NSCLC with KRAS p.G12C Mutation: CodeBreak 100
  • Guardant360 CDx Test - Pembrolizumab - Product Status
  • Guardant360 CDx Test - Pembrolizumab - Product Description
  • Guardant360 CDx Test - Tepotinib - Product Status
  • Guardant360 CDx Test - Tepotinib - Product Description
  • Guardant360 Companion Diagnostic Assay - Glesatinib - Product Status
  • Guardant360 Companion Diagnostic Assay - Glesatinib - Product Description
  • GuardantOMNI Test - Imfinzi - Product Status
  • GuardantOMNI Test - Imfinzi - Product Description
  • LUNAR-2 Assay - Product Status
  • LUNAR-2 Assay - Product Description
  • LUNAR-2 Assay - Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode
  • Next-Generation CGP Tissue Assay - Product Status
  • Next-Generation CGP Tissue Assay - Product Description
Guardant Health Inc, Key Employees
  • Guardant Health Inc, Subsidiaries
  • Glossary
List of Figures
  • Guardant Health Inc Pipeline Products by Equipment Type
  • Guardant Health Inc Pipeline Products by Development Stage
  • Guardant Health Inc Ongoing Clinical Trials by Trial Status
Note: Product cover images may vary from those shown
  • Thermo Fisher Scientific Inc
  • Roche Molecular Systems Inc
  • Qiagen NV
  • Novartis Pharmaceuticals Corp
  • Natera Inc
  • NantHealth Inc
  • InVitae Corp
  • Illumina Inc
  • ElSohly Laboratories Inc
  • BioGenex Laboratories Inc
Note: Product cover images may vary from those shown
Adroll
adroll